HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced today that the Company entered into a Research Agreement with Eisai, Co. Ltd. a pharmaceutical company based in Tokyo, Japan. The Research Agreement funds biomarker development for certain proteins and their modifications associated with molecular targeted agents. Leon Terstappen, Chief Scientific Officer of Immunicon said, “We are pleased to work with Eisai on these important biomarkers. If successful, these proteins and their modifications will help to identify patients that may benefit from targeted therapies or to monitor treatment efficacy.”
